Search results
Results From The WOW.Com Content Network
Oxytetracycline, like other tetracyclines, is used to treat many infections, both common and rare.Its better absorption profile makes it preferable to tetracycline for moderately severe acne at a dosage of 250–500 mg four times a day for usually six to eight weeks at a time, but alternatives should be sought if no improvement occurs by three months.
(formerly known as TP-434) received FDA approval on August 27, 2018, for treatment of complicated intra-abdominal infections. [54] Sarecycline: 16+ hours (long) (formerly known as WC 3035) received FDA approval on October 1, 2018, for treatment of moderate to severe acne vulgaris. [55] Sarecycline is a narrow-spectrum antibiotic. [56] [57 ...
Tetracycline displayed higher potency, better solubility, and more favorable pharmacology than the other antibiotics in its class, leading to its FDA approval in 1954. The new compound was one of the first commercially successful semi-synthetic antibiotics that was used, and laid the foundation for the development of Sancycline, Minocycline ...
NovoBiotic Pharmaceuticals owns the patent rights [3] to teixobactin, an antibiotic that has been shown to be active against pathogenic Gram-positive bacteria that have developed resistance to available approved antibiotics. The discovery and characterization of the compound was reported in 2015 in a collaboration between NovoBiotic ...
FDA has approved five different drugs for use in aquaculture as long as the seafood contains less than a mandated maximum residue limit: florfenicol, sulfamerazine, chorionic gonadotropin, oxytetracycline dihydrate, oxytetracycline hydrochloride, as well as a drug combination of sulfadimethoxine and ormetoprim. [7]
Mirikizumab, a drug currently approved by the Food and Drug Administration (FDA) for the treatment of ulcerative colitis, also sends Crohn's disease into clinical remission, new findings suggest.
In December 2008, the U.S. Food and Drug Administration (FDA) declined to approve oritavancin without additional studies, and an EU application was withdrawn. [citation needed] In 2009, The Medicines Company acquired the development rights, completed clinical trials and submitted a new drug application to the FDA in February 2014. [26]
In combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant ...